Enanta Pharmaceuticals Inc (ENTA) stock
ENTANasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026Score 2/3018% above fair value
$10.99−0.21 (-1.87%)
Close on Nov 13, 2026Market cap $320.09MP/E –Yield –
Enanta Pharmaceuticals enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Enanta Pharmaceuticals's enterprise value was $148.29M on Nov 11, 2026, against $113.12M a year earlier. Over the last 5 years it ranged from -$196.66M to $1.27B, with a median of $148.29M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $148.29M | -0.1% |
| 2025 | Dec 31, 2025 | $148.41M | – |
| 2024 | Dec 31, 2024 | -$125.21M | – |
| 2023 | Dec 29, 2023 | -$171.74M | -123.9% |
| 2022 | Dec 30, 2022 | $717.97M | -43.4% |
| 2021 | Dec 31, 2021 | $1.27B | +176.8% |
| 2020 | Dec 31, 2020 | $458.59M | -48.0% |
| 2019 | Dec 31, 2019 | $882.02M | -17.2% |
| 2018 | Dec 31, 2018 | $1.07B | +18.6% |
| 2017 | Dec 29, 2017 | $898.29M | +44.6% |
| 2016 | Dec 30, 2016 | $621.13M | +31.4% |
| 2015 | Dec 31, 2015 | $472.82M | -44.7% |
| 2014 | Dec 31, 2014 | $854.77M | +120.5% |
| 2013 | Dec 31, 2013 | $387.64M | – |
See a number that looks wrong?